JPMorgan Chase & Co. 13D and 13G filings for PMV Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-04-09 1:17 pm Sale |
2024-03-29 | 13G | PMV Pharmaceuticals, Inc. PMVP |
JPMORGAN CHASE & CO JPM |
15,573 0.000% |
-3,659,241 (-99.58%) |
Filing |
| 2024-01-23 09:40 am Sale |
2023-12-29 | 13G | PMV Pharmaceuticals, Inc. PMVP |
JPMORGAN CHASE & CO JPM |
3,674,814 7.100% |
-329,953 (-8.24%) |
Filing |
| 2023-01-25 12:18 pm Sale |
2022-12-30 | 13G | PMV Pharmaceuticals, Inc. PMVP |
JPMORGAN CHASE & CO JPM |
4,004,767 8.700% |
-580,692 (-12.66%) |
Filing |
| 2022-07-07 10:06 am Purchase |
2022-06-30 | 13G | PMV Pharmaceuticals, Inc. PMVP |
JPMORGAN CHASE & CO JPM |
4,585,459 10.000% |
1,419,009 (+44.81%) |
Filing |
| 2022-01-26 11:54 am Purchase |
2021-12-31 | 13G | PMV Pharmaceuticals, Inc. PMVP |
JPMORGAN CHASE & CO JPM |
3,166,450 6.900% |
3,166,450 (New Position) |
Filing |